Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion

Hepatology

Volumn 27, Issue 1, 1998, Pages 35-41

  Guevara, M ^a   Gines, P ^a   Fernandez Esparrach, G ^a   Sort, P ^a   Salmeron, J M ^a   Jimenez, W ^a   Arroyo, V ^a   Rodes, J ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ORNIPRESSIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CREATININE CLEARANCE; GLOMERULUS FILTRATION RATE; HEPATORENAL SYNDROME; HUMAN; KIDNEY CIRCULATION; KIDNEY FUNCTION; KIDNEY PERFUSION; KIDNEY PLASMA FLOW; KIDNEY VASCULAR RESISTANCE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASOCONSTRICTION;

EID: 0031962226     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510270107     Document Type: Article

References (46)

1. 1 Levy M. Hepatorenal syndrome. Kidney Int 1993 ; 43: 737–753. MEDLINE
2. 2 Schrier RW, Niederberger M, Weigert A, Ginès P. Peripheral arterial vasodilation: Determinant of functional spectrum of cirrhosis. Semin Liver Dis 1994 ; 14: 14–22. MEDLINE
3. 3 Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, Reynolds TB, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996 ; 23: 164–173. MEDLINE
4. 4 Epstein M. Hepatorenal syndrome. In: Epstein, M ed. The Kidney in Liver Disease, 4th Ed. Philadelphia, Pa: Hanley & Belfus. 1996 ; 75–108.
5. 5 Bataller R, Ginès P, Guevara M, Arroyo V. Hepatorenal syndrome. Semin Liver Dis 1997 ; 17: 233–248. MEDLINE
6. 6 Laffi G, La Villa G, Gentilini P. Pathogenesis and management of the hepatorenal syndrome. Semin Liver Dis 1994 ; 14: 71–81. MEDLINE
7. 7 Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988 ; 8: 1151–1157. MEDLINE
8. 8 Berde B, Boissonas RA, Huguenin RL, Sturmer E. Vasopressin analogues with selective pressor activity. Experientia 1964 ; 2: 42–43.
9. 9 Dunér H, Kövamees A, Malström G, Pernow B. Effect of ornithine‐8‐vasopressin on hemodynamics and diuresis in man. Acta Chir Scand 1971 ; 137: 201–207. MEDLINE
10. 10 Coleman AJ, Baker LW. Some cardiovascular effects of ornithine‐8‐vasopressin: a new surgical vasoconstrictor agent. Br J Anaesth 1973 ; 45: 511–513. MEDLINE
11. 11 Ginès P, Jiménez W, Arroyo V, Navasa M, Lopez C, Titó L, Serra A, et al. Atrial natriuretic factor in cirrhosis with ascites: plasma levels, cardiac release and splanchnic extraction. Hepatology 1988 ; 8: 636–642. MEDLINE
12. 12 Heyrovsky A. A new method for the determination of inulin in plasma and urine. Clin Chim Acta 1956 ; 1: 470–474.
13. 13 Brun C. A rapid method for the determination of para‐aminohippuric acid and kidney function tests. J Lab Clin Med 1951 ; 37: 955–958.
14. 14 Zelch MG, Geisinger MA, Risius B. Tongue necrosis after intraarterial vasopressin therapy. Am J Roentgenol 1985 ; 144: 1283–1284.
15. 15 Rector WG. Drug therapy for portal hypertension. Ann Intern Med 1986 ; 105: 96–107. MEDLINE
16. 16 Fruhstorfer H, Heisler M. Dose‐response relation of ornipressin with regard to vasoconstriction in human skin. Br J Anaesth 1994 ; 73: 220–224. MEDLINE
17. 17 Collins IS. Multicentric clinical trial of a vasoconstrictor‐ornithine vasopressin (POR‐8, Sandoz). N Z Med J 1972 ; 76: 77–81. MEDLINE
18. 18 Hirasawa A, Shibata K, Kotosai K, Tsujimoto G. Cloning, functional expression and tissue distribution of human cDNA for the vascular‐type vasopressin receptor. Biochem Biophys Res Commun 1994 ; 203: 72–79. MEDLINE
19. 19 Valentin N, Nielsen OV. Vasoconstrictors and general anaesthesia. Acta Anaesth Scand 1969 ; 13: 63–75.
20. 20 Einstein R, Angus JA, Cobbin LB, Goodman AH. Cardiovascular effects of ornithine‐8‐vasopressin (“POR‐8”). Med J Aust 1971 ; 2: 798–800. MEDLINE
21. 21 Lenz K, Hörtnagl H, Druml W, Grimm G, Laggner A, Schneeweisz B, Kleinberger G. Beneficial effect of 8‐ornithine vasopressin on renal dysfunction in decompensated cirrhosis. Gut 1989 ; 30: 90–96. MEDLINE
22. 22 Lenz K, Hörtnagl H, Druml W, Reither H, Schmid R, Schneeweisz B, Laggner A, et al. Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis. Gastroenterology 1991 ; 101: 1060–1067. MEDLINE
23. 23 Tristani FE, Cohn JN. Systemic and renal hemodynamics in oliguric hepatic failure: effect of volume expansion. J Clin Invest 1967 ; 46: 1894–1906. MEDLINE
24. 24 Epstein M, Scheneider N, Belefer B. Relationship of systemic and intrarenal hemodynamics in cirrhosis. J Lab Clin Med 1979 ; 89: 1175–1187.
25. 25 Fernández‐Seara J, Prieto J, Quiroga J, Zozaya J, Cobos M, Rodriguez‐Eire J, García‐Plaza A, et al. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology 1989 ; 97: 1304–1312. MEDLINE
26. 26 Maroto A, Ginès P, Arroyo V, Ginès A, Saló J, Clària J, Jiménez W, et al. Brachial and femoral artery blood flow in cirrhosis: relationship to kidney dysfunction. Hepatology 1993 ; 17: 788–793. MEDLINE
27. 27 Alvestrand A, Bergstrom J. Glomerular hyperfiltration after protein ingestion, during glucagon infusion, and in insulin‐dependent diabetes is induced by a liver hormone: deficient production of this hormone in hepatic failure causes hepatorenal syndrome. Lancet 1984 ; 1: 195–197. MEDLINE
28. 28 Lang F, Gerok W, Häussinger D. New clues to the pathophysiology of hepatorenal failure. Clin Invest Med 1993 ; 71: 93–97.
29. 29 Shapiro MD, Nicholls KM, Groves BM, Kluge R, Chung HM, Bichet D, Schrier RW. Interrelationship between cardiac output and vascular resistance as determinants of effective arterial blood volume in cirrhotic patients. Kidney Int 1985 ; 28: 206–211. MEDLINE
30. 30 Nicholls KM, Shapiro MD, Kluge R, Chung HM, Bichet D, Schrier RW. Sodium excretion in advanced cirrhosis: effect of expansion of central volume and suppression of plasma aldosterone. Hepatology 1986 ; 6: 235–238. MEDLINE
31. 31 Pladson TR, Parrish RM. Hepatorenal syndrome: recovery after peritoneovenous shunt. Arch Intern Med 1977 ; 137: 1248–1249. MEDLINE
32. 32 Shroeder ET, Anderson GH, Smulyan H. Effects of a portocaval or peritoneovenous shunt on renin in the hepatorenal syndrome. Kidney Int 1979 ; 15: 54–61. MEDLINE
33. 33 Wong PY, Carroll RE, Lipinsky TL, Capone RR. Studies on the renin‐angiotensin‐aldosterone system in patients with cirrhosis and ascites: effect of saline and albumin infusion. Gastroenterology 1979 ; 77: 1171–1176. MEDLINE
34. 34 Papper S. Hepatorenal syndrome. In: Epstein M, ed. The Kidney in Liver Disease, 2nd ed. New York, NY: Elsevier Science Publishing Company Inc ; 1983: 87–106 1171–1176.
35. 35 Ginès A, Escorsell A, Ginès P, Saló J, Jiménez W, Inglada L, Navasa M, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993 ; 105: 229–236. MEDLINE
36. 36 Levicki JA, Protter AA. Physiological studies of the natriuretic peptide family. In: Laragh, JH Brenner, BH eds. Hypertension: pathophysiology, diagnosis and management, Vol 1, 2nd ed. New York, NY: Raven. 1995 ; 1029–1053.
37. 37 Angeli P, Jiménez W, Arroyo V, Mackenzie HS, Zhang PL, Clària J, Rivera F, et al. Renal effects of natriuretic peptide receptor blockade in cirrhotic rats with ascites. Hepatology 1994 ; 20: 948–954. MEDLINE
38. 38 Navar LG, Inscho EW, Majid SA, Imid JD, Harrison‐Bernard LM, Mitchell KD. Paracrine regulation of the renal microcirculation. Physiol Rev 1996 ; 72: 425–535.
39. 39 Rosivall L, Narcates J, Oparil S, Navar LG. De novo intrarenal formation of angiotensin II during control and enhanced renin secretion. Am J Physiol 1987 ; 252: F1118–F1123. MEDLINE
40. 40 Llach J, Ginès P, Arroyo V, Salmerón JM, Ginès A, Jiménez W, Gaya J, et al. Effect of dipyridamole on kidney function in cirrhosis. Hepatology 1993 ; 17: 59–66. MEDLINE
41. 41 Moore K, Wendon J, Frazer M, Karani J, Williams R, Badr K. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med 1992 ; 327: 1774–1778. MEDLINE
42. 42 Kon V, Yoshioka T, Fogo A, Ichikawa L. Glomerular actions of endothelin in vivo. J Clin Invest 1989 ; 83: 1762–1767. MEDLINE
43. 43 Soper PR, Latif AB, Bending MR. Amelioration of hepatorenal syndrome with selective endothelin‐A antagonist. Lancet 1996 ; 347: 1842–1843. MEDLINE
44. 44 Conn HO, Ramsby GR, Storer EH, Mutchnick MG, Joshi PH, Phillips MM, Cohen GA, et al. Intraarterial vasopressin in the treatment of upper gastrointestinal hemorrhage: a prospective, controlled clinical trial. Gastroenterology 1975 ; 68: 211–216. MEDLINE
45. 45 Chojkier M, Groszmann RJ, Atterbury E, Bar‐Meir S, Blei AT, Frankel J, Glickman MG, et al. A controlled‐comparison of continuous intraarterial and intravenous infusions of vasopressin in hemorrhage from esophageal varices. Gastroenterology 1979 ; 77: 540–546. MEDLINE
46. 46 Fogel MR, Knauer M, Andres LL, Mahal AS, Stein DET, Kemeny J, Rinki MM, et al. Continuous intravenous vasopressin in active upper gastrointestinal bleeding. Ann Intern Med 1982 ; 96: 565–569. MEDLINE